The overall goals of the Protocol Specific Research Support are to promote the conduct of novel therapeutic trials by Cancer Center Faculty and to provide research nursing and data management support for high priority Cancer Center investigator-initiated clinical trials that lack extramural support. The CCSG institutional clinical trials support represents an essential funding mechanism for investigator-initiated translational research efforts. When protocols written by Cancer Center members are submitted to the Protocol Review and Monitoring System (PRMS) Committee, the investigator has the option to request CCSG support if he/she does not have an adequate source of funds to provide nursing and data management and he/she feels that the trial has high scientific merit. Prior to the PRMS Committee meeting, the Chairman of the Committee confirms the insufficient nursing/data management support from the Clinical Protocol and Data Management (CPDM) Shared Facility administrator;the committee review includes a committee recommendation on CCSG support to the Center Director. The criteria used include high scientific merit (<2.0 on a 1-5 scoring system), translational nature of the study and a priority area of the Cancer Center's PRMS Committee review. The final approval on such trials rests with the Center Director. Since the last funding period 13 studies have received funding through this mechanism and these studies have accrual of 283 patients. During the next funding period, we will continue to support our investigator-initiated clinical trials program. We have identified faculty slots for three additional clinical trialists in the Division of Hematology-Oncology and at least one faculty slot in the Department of Surgery to expand our investigator-initiated clinical trial portfolio. Collaboration of clinical investigators with our new shared facilities and the pre-clinical scientists will enhance our ability to undertake translational studies with meaningful biologic endpoints.
Support for new ideas at the earliest stages is critical to development of clinical research. Protocol Specific Research Support provides funding early in the development of a concept when preliminary data may be required to prove feasibility needed to extramural peer reviewed funding and/or initiation of pilot phase 11 trials. This support also allows demonstration of feasibility and preliminary anti-tumor efficacy for trials considered high risk by other mechanisms.
|Kim, H-G; LeGrand, J; Swindle, C S et al. (2017) The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia. Leukemia 31:2267-2271|
|Miller, Aubrey L; Garcia, Patrick L; Pressey, Joseph G et al. (2017) Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors. Sci Rep 7:17787|
|Childers, Noel K; Grenett, Hernan; Morrow, Casey et al. (2017) Potential Risk for Localized Aggressive Periodontitis in African American Preadolescent Children. Pediatr Dent 39:294-298|
|Kasten, Benjamin B; Arend, Rebecca C; Katre, Ashwini A et al. (2017) B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol 47:23-30|
|Prince, Andrew C; Jani, Aditi; Korb, Melissa et al. (2017) Characterizing the detection threshold for optical imaging in surgical oncology. J Surg Oncol 116:898-906|
|McConnell, Matthew; Feng, Shengmei; Chen, Wei et al. (2017) Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity. Oncotarget 8:47675-47690|
|Kumar, Ranjit; Yi, Nengjun; Zhi, Degui et al. (2017) Identification of donor microbe species that colonize and persist long term in the recipient after fecal transplant for recurrent Clostridium difficile. NPJ Biofilms Microbiomes 3:12|
|Van Beusecum, J P; Zhang, S; Cook, A K et al. (2017) Acute toll-like receptor 4 activation impairs rat renal microvascular autoregulatory behaviour. Acta Physiol (Oxf) 221:204-220|
|Ghosh, Arindam P; Willey, Christopher D; Anderson, Joshua C et al. (2017) Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma. Oncotarget 8:29220-29232|
|Shah, Spandan; Gibson, Andrew W; Ji, Chuanyi et al. (2017) Regulation of FcR? function by site-specific serine phosphorylation. J Leukoc Biol 101:421-428|
Showing the most recent 10 out of 692 publications